论文部分内容阅读
乙型肝炎已列为国家重点科研课题之一。据估计,我国乙型肝炎病毒表面抗原携带者达一亿人以上,现症病人也不少,其中又大多数是慢性病人。而且乙型肝炎病毒可能是“癌中王”——肝癌的致病因子,大约80％的肝癌被认为是乙型肝炎病毒感染的后果。因此,阻断乙型肝炎的传播乃是我国医药工作者当前的迫切任务。在预防乙型肝炎的研究中,已有特效药:乙型肝炎疫苗及乙型肝炎高效价免疫球蛋白问世,现摘要介绍如下:
Hepatitis B has been listed as one of the key national research topics. It is estimated that there are over 100 million carriers of hepatitis B virus surface antigen in our country and many patients are now infected, most of whom are chronic patients. Hepatitis B virus may be the “king of cancer” - the causative agent of liver cancer. About 80% of liver cancer is considered to be the consequence of hepatitis B virus infection. Therefore, blocking the spread of hepatitis B is an urgent task for medical workers in our country. In the prevention of hepatitis B in the study, there are effective drugs: Hepatitis B vaccine and hepatitis B high titer immunoglobulin come out, the summary is as follows: